Tus Pharmaceutical Group Co Ltd (000590) — Strategic Asset Allocation Index
Tus Pharmaceutical Group Co Ltd (000590) has a Strategic Asset Allocation Index of 41.6% as of September 2023. Strategic assets (PP&E of CN¥294.74 Million plus long-term investments of CN¥-) total CN¥294.74 Million, measured against net assets of CN¥708.89 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Tus Pharmaceutical Group Co Ltd (000590) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Tus Pharmaceutical Group Co Ltd Strategic Asset Allocation Index (2000–2022)
This chart shows how Tus Pharmaceutical Group Co Ltd's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of September 2023, the index stands at 41.6%, representing strategic assets of CN¥294.74 Million against net assets of CN¥708.89 Million CNY. For live market cap and overall valuation, see Tus Pharmaceutical Group Co Ltd (000590) total market value.
Annual Strategic Asset Allocation Index for Tus Pharmaceutical Group Co Ltd (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Tus Pharmaceutical Group Co Ltd from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Tus Pharmaceutical Group Co Ltd (000590) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 41.2% | CN¥289.75 Million | CN¥289.75 Million | CN¥- | CN¥702.49 Million | ▲ +5.9 pp |
| 2021 | 35.3% | CN¥240.89 Million | CN¥240.89 Million | CN¥- | CN¥682.32 Million | ▲ +0.5 pp |
| 2020 | 34.8% | CN¥224.73 Million | CN¥224.73 Million | CN¥- | CN¥644.88 Million | ▲ +2.5 pp |
| 2019 | 32.3% | CN¥200.96 Million | CN¥200.96 Million | CN¥- | CN¥622.16 Million | ▲ +2.7 pp |
| 2018 | 29.6% | CN¥171.35 Million | CN¥171.35 Million | CN¥- | CN¥579.72 Million | ▲ +1.0 pp |
| 2017 | 28.5% | CN¥166.37 Million | CN¥164.78 Million | CN¥1.58 Million | CN¥583.33 Million | ▼ -31.3 pp |
| 2016 | 59.8% | CN¥157.80 Million | CN¥157.80 Million | CN¥- | CN¥263.96 Million | ▼ -13.9 pp |
| 2015 | 73.7% | CN¥151.58 Million | CN¥151.58 Million | CN¥- | CN¥205.79 Million | ▼ -14.3 pp |
| 2014 | 88.0% | CN¥161.96 Million | CN¥161.96 Million | CN¥- | CN¥184.11 Million | ▼ -11.4 pp |
| 2013 | 99.4% | CN¥267.81 Million | CN¥267.81 Million | CN¥- | CN¥269.51 Million | ▲ +34.7 pp |
| 2012 | 64.7% | CN¥309.57 Million | CN¥309.57 Million | CN¥- | CN¥478.58 Million | ▼ -24.0 pp |
| 2011 | 88.7% | CN¥311.14 Million | CN¥311.14 Million | CN¥- | CN¥350.83 Million | ▼ -15.2 pp |
| 2010 | 103.9% | CN¥289.78 Million | CN¥289.78 Million | CN¥- | CN¥278.88 Million | ▼ -14.5 pp |
| 2009 | 118.5% | CN¥273.89 Million | CN¥273.89 Million | CN¥- | CN¥231.22 Million | ▲ +34.6 pp |
| 2008 | 83.9% | CN¥270.76 Million | CN¥270.76 Million | CN¥- | CN¥322.78 Million | ▲ +14.9 pp |
| 2007 | 68.9% | CN¥211.79 Million | CN¥211.79 Million | CN¥- | CN¥307.22 Million | ▲ +5.8 pp |
| 2006 | 63.2% | CN¥171.35 Million | CN¥171.35 Million | CN¥- | CN¥271.26 Million | ▼ -33.0 pp |
| 2005 | 96.2% | CN¥258.31 Million | CN¥258.31 Million | CN¥- | CN¥268.54 Million | ▲ +16.8 pp |
| 2004 | 79.3% | CN¥212.29 Million | CN¥212.29 Million | CN¥- | CN¥267.57 Million | ▼ -5.3 pp |
| 2003 | 84.7% | CN¥219.44 Million | CN¥219.44 Million | CN¥- | CN¥259.16 Million | ▼ -5.9 pp |
| 2002 | 90.6% | CN¥254.41 Million | CN¥254.41 Million | CN¥- | CN¥280.91 Million | ▲ +1.3 pp |
| 2001 | 89.3% | CN¥248.82 Million | CN¥248.82 Million | CN¥- | CN¥278.65 Million | ▲ +33.3 pp |
| 2000 | 56.0% | CN¥212.83 Million | CN¥212.83 Million | CN¥- | CN¥380.02 Million | — |